Acute Myeloid Leukemia

The novel targeted radiotherapy iomab-B led to the disappearance of all signs of cancer and an improvement in event-free survival compared with physician’s choice of treatment.

I’ve been watching a YouTube channel about Borneo orangutans, and realized that these animals remind me of myself after cancer.

From ballooning ankles to rashes, there were multiple chemotherapy side effects that I had to deal with — here’s how I did it.

As a recovering addict, I was nervous about the painkillers that would come alongside my cancer treatment, but I soon learned that they would be needed.

“Was I OK with dying? Would I still be there for my dog? Can I still smoke?” — all these thoughts entered my mind when my oncologist told me that I had leukemia.

The FDA granted a priority review to the oral drug quizartinib for the treatment of a form of acute myeloid leukemia, one of the more common types of leukemia.

After breaking 20 years of sobriety, I received even worse news: my leukemia had relapsed, and I’d need a bone marrow transplant. Thankfully, my family and treatment team lifted me up during this difficult time.

The Food and Drug Administration put a full clinical hold on a study of the novel drug FHD-286 in patients with acute myelogenous leukemia and myelodysplastic syndrome after study data showed an increase in a potentially fatal side effect.

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.

The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors.

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.

All clinical trials investigating the combination of magrolimab and the chemotherapy Onureg have been paused due to unforeseen serious side effects experienced by patients with various blood cancers receiving the treatment.

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

Study results showed that CPI-613 did not improve survival in patients with metastatic adenocarcinoma of the pancreas.

An abundance of clinical trials is giving patients with acute myeloid leukemia (AML) hope for a better future.

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

“We are fortunate now to live in an era where we have nine new drugs approved (for AML) just in the last five years,” says an expert from The University of Texas MD Anderson Cancer Center.

“More and more (patients and physicians) need to work together in partnership throughout the cancer journey in order to optimize and make the journey the best possible that we can for every single patient,” says an expert from the Roswell Park Comprehensive Cancer Center.

A woman shares the story of her journey with multiple cancer types, including the same one that her mother died from.

Scientists have identified a potentially valuable genetic target in children with acute myeloid leukemia that could lead to further studies in immunotherapy drugs for the disease.

An analysis of more than 3.5 million children born between January 1996 and December 2016 demonstrated a stronger association between Down syndrome and acute myeloid leukemia risk than has been previously reported.

Treatment with a novel therapy as a single agent, or in combination with Venclexta, demonstrated a manageable safety profile and antileukemic effects in patients with relapsed/refractory acute myeloid leukemia. The study authors, however, note that more research is needed.

Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.